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The activity of linezolid, a new oxazolidinone, was tested against 862 Gram-positive cocci
isolated in Italy and compared with the activities of 12 antibiotics. Overall, MIC90s for
linezolid (2–4 mg/L) indicated an in vitro activity comparable to that of vancomycin in
methicillin-resistant Staphylococcus aureus (4 mg/L), S. epidermidis (2 mg/L) and methi-
cillin-susceptible strains. Enterococcus faecalis strains were susceptible to linezolid (MIC90
2–4 mg/L), glycopeptides and b-lactams. In E. faecium, only glycopeptides (MIC90 2 mg/
L) and linezolid (MIC90 2 mg/L) were active. Linezolid was the only drug active against
two strains of Enterococcus showing a VanA phenotype. Owing to its antibacterial profile,
linezolid represents a promising drug for the treatment of Gram-positive infections.
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Resistance to antimicrobial drugs is a global pro-
blem. Multiresistant pathogens are distributed
worldwide, and the threat of spread of antibiotic
resistance is increasing. As a consequence, the
efficacy of available antibiotics is decreasing, tip-
ping the balance in favor of multiresistant patho-
gens [1–3].
For patients infected with these resistant organ-
isms, effective antimicrobial therapy has become
exceedingly difficult to practice. As a result, new
antimicrobial agents possessing unique mecha-
nisms of action are urgently needed to manage
infections caused by these resistant strains. Line-
zolid is a member of a new class of antibacterials,
the oxazolidinones, that are chemically unrelated
to currently available agents [4]. Linezolid is avail-
able for both oral and parenteral usage, and is
highly active against Gram-positive organisms;
resistance is seldom selected in vitro [5]. Since
the potency of a drug may be influenced by the
nature of the epidemiologic environment into
which it is introduced, the activity of linezolid
was assessed against recently isolated enterococci
and staphylococci, isolated from different clinical
specimens in high-risk wards and collected in clin-
ical microbiology laboratories in Italy during 1999.
Eight hundred and sixty-two Gram-positive
cocci comprising 426 methicillin-resistant Staphy-
lococcus aureus (MRSA) strains, 83 methicillin-sus-
ceptible Staphylococcus aureus (MSSA) strains, 80
methicillin-resistant Staphylococcus epidermidis
(MRSE) strains, 22 methicillin-susceptible Staphy-
lococcus epidermidis (MSSE) strains, 24 coagulase-
negative staphylococcal (CoNS) strains, 200 Entero-
coccus faecalisstrainsand27E. faeciumstrains, freshly
isolated from clinical specimens, were collected
from 29 microbiological laboratories distributed
throughout Italy over a 3-month period during
1999. Following a protocol agreed upon by all parti-
cipants, each center was asked to provide to the
reference centers (Laboratories of Microbiology,
University of Catania and Genoa, Italy) staphylo-
coccal and enterococcal strains isolated in high-risk
wards (hematology, surgery and intensive care
units) from the following specimens: blood, urine,
prostatic massages, cerebrospinal fluids, catheters,
bronchoalveolar lavages, sputa and pus. Only
one isolate per patient was accepted and tested.
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Repetitivestrainswere discarded,andallpathogens
were re-identified to species level. All strains were
stored at 80 8C until use. Along with the clinical
isolates, the reference quality control strains Staphy-
lococcus aureus ATCC 29213 and E. faecalis ATCC
29212 were used.
Susceptibility tests were performed by micro-
dilution, following NCCLS guidelines [6,7]. Anti-
biotics were supplied by the manufacturers:
linezolid and clindamycin (Pharmacia & Upjohn,
Milan, Italy), amoxicillin–clavulanate (Smith Kline
Beecham, Milan, Italy), vancomycin (Eli Lilly,
Sesto Fiorentino, Italy), teicoplanin (Aventis
Pharma, Milan, Italy), and ciprofloxacin (Bayer,
Milan, Italy). Gentamicin, erythromycin, chloram-
phenicol, rifampin, streptomycin, oxacillin and
penicillin were purchased from Sigma-Aldrich
(Milan, Italy).
Overall, staphylococci and enterococci were
most frequently isolated from blood cultures
(31.3%), followed by urine and lower respiratory
tract infection specimens (17.6% and 16.6%,
respectively). About 10% of the isolates were asso-
ciated with intravascular device implants. Methi-
cillin-resistant staphylococci, Staphylococcus aureus
and coagulase-negative species account for 82.4%
of all staphylococcal isolates in high-risk wards in
Italy in the period included in the study. Methi-
cillin-resistant strains were more frequently iso-
lated from blood cultures and lower respiratory
tract infection specimens. In Tables 1–3, the acti-
vities of linezolid and comparator agents against
the 523 methicillin-resistant staphylococci, express-
ed in terms of MIC50, MIC90, and percentages of
resistance, are shown. Overall, MIC90 values for
linezolid (2–4 mg/L) indicate in vitro potency
Table 1 In vitro activity of linezolid
compared with 12 antimicrobial
agents (mg/L) against 426 methicil-
lin-resistant Staphylococcus aureus
strains
Antimicrobial Range MIC50 MIC90 % R
Linezolid 0.5–4 2 4 –
Penicillin 0.06 to >4 >4 >4 99.3
Imipenem <0.5 to >64 64 >64 89.4
Amoxicillin–clavulanate <0.5 to >64 64 >64 99.5
Vancomycin <1–2 <1 2 0
Teicoplanin <1–8 2 8 0
Gentamicin <0.5 to >64 >64 >64 97.4
Erythromycin <0.25 to >32 >32 >32 90.3
Clindamycin <0.25 to >32 >32 >32 98.1
Ciprofloxacin <0.25 to >32 >32 >32 93.9
Chloramphenicol 2 to >128 16 128 68.5
Rifampin <0.5 to >64 8 >64 57.3
Co-trimoxazole <0.5 to >64 <0.5 16 11.7
R, resistance.
Table 2 In vitro activity of linezolid
compared with 12 antimicrobial
agents (mg/L) against 80 methicil-
lin-resistant Staphylococcus epidermi-
dis strains
Antimicrobial Range MIC50 MIC90 % R
Linezolid 0.5–4 2 2 –
Penicillin 1 to >4 >4 >4 100
Imipenem <0.5 to >64 32 64 78.7
Amoxicillin–clavulanate <0.5 to >64 32 64 88.7
Vancomycin <1–4 <1 2 0
Teicoplanin <1–8 4 8 0
Gentamicin <0.5 to >64 64 >64 80.0
Erythromycin <0.25 to >32 >32 >32 95.0
Clindamycin <0.25 to >32 >32 >32 95.0
Ciprofloxacin <0.25 to >32 32 >32 73.7
Chloramphenicol <1 to >128 64 >128 57.5
Rifampin <0.5 to >64 2 >64 52.5
Co-trimoxazole <0.5–64 1 64 45.0
R, resistance.
Concise Communication 369
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 368–372
comparable to that of vancomycin and teicoplanin
in MRSA (2 and 8 mg/L), MRSE (2 and 8 mg/L)
and MRCoN strains (2 and 8 mg/L). Methicillin-
resistant staphylococci were significantly resistant
to all antibiotics tested, with the exception of glyco-
peptidesandlinezolid.AmongMRSAstrains,90.3%
were resistant to erythromycin, 68.5% to chloram-
phenicol, 97.4% to gentamicin, 93.9% to ciproflox-
acin and 11.7% to co-trimoxazole. Comparable data,
withslightvariationsinthepercentagesofresistance
to co-trimoxazole and chloramphenicol, were
obtained for MRSE and MRCoN strains. Linezolid
showed excellent activity against the 112 strains of
methicillin-susceptible staphylococci, with MIC90
values2–4 mg/L(datanotshown).Against thesame
isolates, the remaining antibiotics also demon-
strated good inhibitory activity.
The E. faecalis strains included in the study were
generally susceptible to glycopeptides and b-lac-
tams and showed an MIC90 value of 4 mg/L for
linezolid (Tables 4 and 5). The strains were charac-
terized by high-level resistance to streptomycin
(62.5%) and gentamicin (46%), and were resistant
to chloramphenicol and rifampin. Against E. fae-
cium, only glycopeptides (MIC90 2 mg/L) and line-
zolid (MIC90 2 mg/L) were active. Over 92.6% of the
strains were resistant to all b-lactams, and 40.7% to
chloramphenicol; 55.5% displayed high-level resis-
tance to streptomycin, and22.2%togentamicin.One
strain of E. faecalis and one strain of E. faecium, both
showing a VanA phenotype (confirmed by PCR),
were susceptible only to linezolid.
In this study, the activity of linezolid was tested
and compared with that of other useful drugs
Antimicrobial Range MIC50 MIC90 % R
Linezolid 0.5–4 1 4 –
Penicillin 1 to >4 >4 >4 100
Imipenem <0.5 to >64 >64 >64 64.7
Amoxicillin–clavulanate <0.5 to >64 32 64 70.6
Vancomycin <1–2 <1 2 0
Teicoplanin <1–64 4 8 5.8
Gentamicin <05 to >64 >64 >64 94.1
Erythromycin 0.5 to >32 >32 >32 94.1
Clindamycin <0.25 to >32 >32 >32 64.7
Ciprofloxacin 0.25 to >32 32 >32 94.1
Chloramphenicol <1 to >128 4 128 41.2
Rifampin 0.5 to >64 1 >64 41.2
Co-trimoxazole <0.5 to >64 16 64 52.9
R, resistance.
Table 3 In vitro activity of linezolid
compared with 12 antimicrobial
agents (mg/L) against 17 methicil-
lin-resistant coagulase-negative Sta-
phylococcus strains
Antimicrobial Range MIC50 MIC90 % R % HLR
Linezolid 0.5–4 1 4 – –
Ampicillin <0.5–64 1 4 7.5 –
Imipenem <0.5 to >64 0.5 4 8.0 –
Vancomycin <1–128 <1 4 1.0 –
Teicoplanin <1–4 <1 <1 0 –
Erythromycin 0.5 to >32 32 >32 95.0 –
Clindamycin 2 to >32 >32 >32 100 –
Ciprofloxacin 0.25 to >32 4 >32 72.0 –
Chloramphenicol 2–128 8 64 45.5 –
Rifampin 0.25 to >32 2 16 44.5 –
Amoxicillin–clavulanate <1–32 <1 2 2.5 –
Streptomycin 64 to >2048 – – – 62.5
Gentamicin <8 to >1024 – – – 46.0
R, resistance; HLR, high-level resistance.
Table 4 In vitro activity of linezolid
(mg/L) compared with 12 antimi-
crobial agents against 200 Enterococ-
cus faecalis strains
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against a large number of staphylococci (635) and
enterococci (227) isolated from high-risk wards by
29 microbiology laboratories, from all over Italy
during 1999, minimizing multiple inclusion of
local epidemic strains. Our study, performed in
a restricted period of time (3 months), confirmed
once more that the frequency of methicillin-resis-
tant multiresistant staphylococci in Italy is an
increasing problem. Methicillin-susceptible sta-
phylococci were inhibited by the majority of anti-
biotics tested, while only linezolid, vancomycin
and teicoplanin were active against methicillin-
resistant strains. It is noteworthy that erythromycin
and clindamycin were not uniformly active against
MSSA, indicating that the constitutive mechanism
of resistance to these drugs was more common
among MRSA [8]. Vancomycin-intermediate Sta-
phylococcus aureus (VISA) was not detected, and
the frequency of hetero-VISA was not assessed in
this study, but, importantly, linezolid has been
shown by other authors to be active against
vancomycin-intermediate staphylococci [9,10].
Vancomycin-resistant enterococci are still rare
(0.5%) in Italy. During this survey, only one strain
of E. faecium and one strain of E. faecalis, possessing
the VanA phenotype and genotype, were isolated.
However, our data highlight the general problem
of treating enterococcal infections because of
increasing resistance to several commonly pre-
scribed antibiotics [10,11].
In Europe, vancomycin-resistant enterococci
have a smaller impact than in the USA [1–10].
The extensive use of glycopeptides is responsible
for their emergence, but differences in the
prevalence of resistant strains noted in various
countries cannot be explained so easily [12,13].
In conclusion, linezolid exhibited good activity
against staphylococci and enterococci (MIC90
values of 1–4 mg/L), irrespective of their resis-
tance to other drugs. These results are in agree-
ment with data from other authors [4,14,15], in
which the spectrum of activity and the unique
mechanism of action of linezolid conferring
absence of cross-resistance to other antimicrobial
classes were underlined.
Information on the breakpoint for susceptibility
of this drug is still not officially available, but the
tentative value of >4 mg/L for resistance sup-
ported by pharmacokinetic data places all our
strains in the susceptibility range [16].
Although the activity of glycopeptides against
Gram-positive cocci seems quite reassuring in the
collection of strains studied (98.5% and 99% of
susceptible staphylococci and enterococci, respec-
tively), and this situation seems to be confirmed by
other local studies [10,17], this condition does not
leave room for complacency, since the evolution of
resistance cannot be easily predicted. As a conse-
quence, evaluation of new drugs is essential.
Among new anti-Gram-positive molecules, line-
zolid seems attractive because of its potential for
wider use, being an oral agent active not only
against MRSA, VISA and vancomycin-resistant
enterococci, but also against important commu-
nity-acquired pathogens such as Streptococcus
pneumoniae (including penicillin-resistant strains)
and Streptococcus pyogenes susceptible and resis-
tant to macrolides [5].
Table 5 In vitro activity of linezolid
(mg/L) compared with 12 antimi-
crobial agents against 27 Enterococ-
cus faecium strains
Antimicrobial Range MIC50 MIC90 % R % HLR
Linezolid 0.5–4 2 2 – –
Ampicillin <0.5 to >64 64 64 62.9 –
Imipenem <0.5 to >64 64 >64 62.9 –
Vancomycin >1 to >128 <1 2 3.7 –
Teicoplanin <1–16 <1 2 3.7 –
Erythromycin 2 to >32 >32 >32 100 –
Clindamycin 0.5 to >32 >32 >32 96.3 –
Ciprofloxacin 1 to >32 >32 >32 92.6 –
Chloramphenicol 2–64 8 32 40.7 –
Rifampin <0.25–32 8 16 92.6 –
Amoxicillin–clavulanate <1–128 8 32 51.8 –
Streptomycin 64 to >2048 – – – 55.5
Gentamicin <8 to >1024 – – – 22.2
R, resistance; HLR, high-level resistance.
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